1185PDParallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted chimeric antigen receptor-T cells for B-cell non-Hodgkin lymphoma

ConclusionsBBz CAR-T showed similar antitumor activity, but a more favorable safety profile, compared with 28z CAR-T. This study proved the competence of BBz CAR-T in B-NHL therapy, at least under our manufacturing process.Legal entity responsible for the studyPeking University Cancer Hospital& Institute.FundingImmunochina Pharmaceuticals Co., Ltd.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research